This study aimed to employ a global antibody profiling strategy to identify novel antibodies and investigate their association with systemic sclerosis (SSc). Methods We implemented this strategy by ...

However, not everyone with MS will have complications. Multiple sclerosis (MS) is a chronic (long-term) condition with symptoms that vary from person to person. With proper management of symptoms ...

If you’ve been diagnosed with multiple sclerosis (MS), it’s time to start exploring treatment options. You’ve got a lot of them, everything from disease-modifying therapies and drugs that help manage ...

The findings contribute to validating systemic administration as an effective delivery approach, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models ...

“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

To keep pace, the traditional service delivery model has given way to what industry analyst Josh Bersin calls Systemic HR — a dynamic and holistic operating system designed to meet the demands ...

Researchers don’t yet fully understand what causes multiple sclerosis (MS) but believe it may develop from a combination of genetic and environmental factors. Identifying these factors can help ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

The integrative physiology of the left ventricle and systemic circulation is fundamental to our understanding of advanced heart failure and cardiogenic shock. In simplest terms, any increase in aortic ...

Back to Healio Macular telangiectasia type 2 is a progressive and relatively rare neurodegenerative disease of the macula that typically affects patients who are older than 40 years of age ...